[Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation]. / Lugar en terapéutica de los medicamentos antagonistas del factor de necrosis tumoral. Parte I: evaluación clínica.
An Med Interna
; 23(1): 37-45, 2006 Jan.
Article
em Es
| MEDLINE
| ID: mdl-16542122
ABSTRACT
Blockade of tumor necrosis factor with monoclonal antibodies, has emerged as one of the most promising therapies in some autoimmune conditions as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn s disease. They have shown effectiveness on reducing symptoms and modifying the progression of the disease. However, they disrupt the balance of inflammatory and immune responses and some risks associated with TNF-blockers have become apparent. The purpose of this article is to review the evidence about benefits and risk associated with the use of TNF-blockers in approved indications and to provide practical recommendations for its use in the management of these conditions.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Fator de Necrose Tumoral alfa
/
Fatores Imunológicos
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
Es
Revista:
An Med Interna
Ano de publicação:
2006
Tipo de documento:
Article